IgA nephropathy laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Ahmed Younes (talk | contribs) No edit summary |
||
Line 2: | Line 2: | ||
{{IgA nephropathy }} | {{IgA nephropathy }} | ||
{{CMG}} | {{CMG}} | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
Revision as of 20:03, 7 April 2017
IgA nephropathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
IgA nephropathy laboratory findings On the Web |
American Roentgen Ray Society Images of IgA nephropathy laboratory findings |
Risk calculators and risk factors for IgA nephropathy laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Laboratory Findings
Initial Evaluation
- Assess all patients with biopsy-proven IgA nephropathy for secondary causes to rule out common causes of secondary IgA nephropathy
- Viral serologies: HIV, HBV, HCV
- Liver function tests
- Electrophoresis of serum immunoglobulins
- Assess the risk of progression and prognosis by the following parameters at diagnosis and at follow-up:
- Blood pressure measurement
- Serum creatinine to estimate glomerular filtration rate (GFR)
- Proteinuria
- Pathological features
A kidney biopsy is to be considered only if signs of AKI and macroscopic hematuria persist for at least 5 days since onset of kidney injury.